Peter M Ravdin
Overview
Explore the profile of Peter M Ravdin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
3823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woodward W, Barlow W, Jagsi R, Buchholz T, Shak S, Baehner F, et al.
JAMA Oncol
. 2020 Jan;
6(4):505-511.
PMID: 31917424
Importance: The 21-gene assay recurrence score is increasingly used to personalize treatment recommendations for systemic therapy in postmenopausal women with estrogen receptor (ER)- or progesterone receptor (PR)-positive, node-positive breast cancer;...
2.
Sparano J, Gray R, Ravdin P, Makower D, Pritchard K, Albain K, et al.
N Engl J Med
. 2019 Jun;
380(25):2395-2405.
PMID: 31157962
Background: The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of...
3.
Larsen V, Barlow W, Yang J, Zhu Q, Liu S, Kwan M, et al.
Clin Breast Cancer
. 2019 Apr;
19(4):225-235.e2.
PMID: 30928413
Introduction: GATA3 is a critical transcription factor in maintaining the differentiated state of luminal mammary epithelial cells. We sought to determine the prognostic and predictive roles of GATA3 genotypes for...
4.
Brauer E, Long E, Melnikow J, Ravdin P, Ganz P
J Oncol Pract
. 2018 Dec;
15(2):e98-e109.
PMID: 30550372
Purpose: According to the Institute of Medicine, high-quality cancer care should include effective communication between clinicians and patients about the risks and benefits, expected response, and impact on quality of...
5.
Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D, et al.
N Engl J Med
. 2018 Jun;
379(2):111-121.
PMID: 29860917
Background: The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if...
6.
Engelhardt E, van den Broek A, Linn S, Wishart G, Rutgers E, van de Velde A, et al.
Eur J Cancer
. 2017 Apr;
78:37-44.
PMID: 28412587
Importance: Online prognostication tools such as PREDICT and Adjuvant! are increasingly used in clinical practice by oncologists to inform patients and guide treatment decisions about adjuvant systemic therapy. However, their...
7.
Lin A, Hsing A, Ravdin P
Cancer Epidemiol Biomarkers Prev
. 2015 Jun;
24(6):998.
PMID: 26033756
No abstract available.
8.
Rutgers E, Piccart-Gebhart M, Bogaerts J, Delaloge S, van t Veer L, Rubio I, et al.
Eur J Cancer
. 2011 Nov;
47(18):2742-9.
PMID: 22051734
Background: The MINDACT (Microarray In Node-negative and 1-3 node positive Disease may Avoid ChemoTherapy) trial investigates the clinical utility of the 70-gene profile (MammaPrint) for the selection of breast cancer...
9.
Rimm D, Nielsen T, Jewell S, Rohrer D, Broadwater G, Waldman F, et al.
J Clin Oncol
. 2011 Apr;
29(16):2282-90.
PMID: 21519016
Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have...
10.
Mook S, J van t Veer L, Rutgers E, Ravdin P, van de Velde A, van Leeuwen F, et al.
J Natl Cancer Inst
. 2011 Feb;
103(7):585-97.
PMID: 21350218
Background: Mammographic screening has led to a proportional shift toward earlier-stage breast cancers at presentation. We assessed whether the method of detection provides prognostic information above and beyond standard prognostic...